Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

368 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Mechanisms of immune evasion by tumors.
Drake CG, Jaffee E, Pardoll DM. Drake CG, et al. Adv Immunol. 2006;90:51-81. doi: 10.1016/S0065-2776(06)90002-9. Adv Immunol. 2006. PMID: 16730261 Review.
Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.
Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG. Olson BM, et al. Cancer Immunol Res. 2017 Dec;5(12):1074-1085. doi: 10.1158/2326-6066.CIR-16-0390. Epub 2017 Oct 19. Cancer Immunol Res. 2017. PMID: 29051161 Free PMC article.
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Murtola TJ, et al. Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. Epub 2015 Dec 29. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26715424 Free PMC article. Clinical Trial.
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.
Bhavsar NA, Bream JH, Meeker AK, Drake CG, Peskoe SB, Dabitao D, De Marzo AM, Isaacs WB, Platz EA. Bhavsar NA, et al. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2561-7. doi: 10.1158/1055-9965.EPI-14-0010. Epub 2014 Aug 22. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 25150281 Free PMC article.
Cancer immunotherapy highlights from the 2014 ASCO Meeting.
Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Harshman LC, et al. Cancer Immunol Res. 2014 Aug;2(8):714-9. doi: 10.1158/2326-6066.CIR-14-0119. Cancer Immunol Res. 2014. PMID: 25092813
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, Pardoll DM, Pai SI. Lyford-Pike S, et al. Cancer Res. 2013 Mar 15;73(6):1733-41. doi: 10.1158/0008-5472.CAN-12-2384. Epub 2013 Jan 3. Cancer Res. 2013. PMID: 23288508 Free PMC article.
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Lipson EJ, et al. Clin Cancer Res. 2013 Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov 20. Clin Cancer Res. 2013. PMID: 23169436 Free PMC article. Clinical Trial.
Current immunotherapeutic strategies in prostate cancer.
Grosso JF, Drake CG. Grosso JF, et al. Surg Oncol Clin N Am. 2007 Oct;16(4):861-71, x. doi: 10.1016/j.soc.2007.07.009. Surg Oncol Clin N Am. 2007. PMID: 18022549 Review.
TNF╬▒ and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG. Francica BJ, et al. Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22. Cancer Immunol Res. 2018. PMID: 29472271 Free PMC article.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. LaFleur MW, et al. J Immunol. 2018 Jan 15;200(2):375-383. doi: 10.4049/jimmunol.1701044. J Immunol. 2018. PMID: 29311378 Free PMC article. Review.
368 results
Jump to page
Feedback